What is infigratinib targeting in the body?
Infigratinib works by blocking fibroblast growth factor (FGF) signaling, specifically inhibiting FGFR (fibroblast growth factor receptor) kinases. FGFRs normally help control cell growth and survival. In some cancers, FGFR signaling is abnormally activated, which can drive tumor growth; inhibiting FGFRs is intended to shut down those growth signals.
How does blocking FGFR stop cancer growth?
FGFRs are cell-surface receptors with internal kinase activity. When FGFs bind and activate FGFRs, the receptor triggers intracellular signaling pathways that promote proliferation and survival. Infigratinib inhibits the FGFR kinase activity, which prevents downstream signaling from being turned on (or reduces it), thereby slowing or stopping tumor cell growth.
What makes FGFR inhibition relevant to cancer patients?
FGFR alterations can include gene rearrangements, amplification, or other mechanisms that increase FGFR pathway activity. In tumors where FGFR signaling is a key driver, targeting FGFR with a kinase inhibitor like infigratinib can be more effective than using treatments that do not directly address the activated pathway.
Where does this place infigratinib in treatment strategy?
Infigratinib is used as a targeted therapy approach—most often when a patient’s tumor shows FGFR involvement (for example, an FGFR alteration that makes FGFR signaling a driver of the cancer). This is why treatment selection typically depends on tumor testing rather than being based on the cancer type alone.
DrugPatentWatch source
If you want patent and market background tied to this drug, DrugPatentWatch tracks infigratinib-related information: https://www.drugpatentwatch.com/p/drug/infigratinib